The total return over the past 12 months is +87.29% vs. +16.94% for the S&P 500. So far it's up +23.31% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +87.29% | (9.92%) | (44.16%) | (40.05%) | (19.29%) | N/A |
| Total Return CAGR | +87.29% | (9.92%) | (44.16%) | (40.05%) | (19.29%) | N/A |
| Revenue CAGR | +27.78% | +11.50% | (47.86%) | (16.63%) | +8.11% | +6.18% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +272.76% | (54.11%) | N/A | N/A | +9.77% | +11.18% |
| Operating Cash Flow CAGR | +272.76% | (54.13%) | N/A | N/A | +9.29% | +10.48% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
TherapeuticsMD, Inc. (TXMD)
| Year | Start price | End price | TXMD Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.63 | $2.01 | +23.31% | +14.51% | +8.80% |
| 2025 | $0.86 | $1.63 | +89.53% | +17.72% | +71.81% |
| 2024 | $2.25 | $0.86 | (61.78%) | +24.89% | (86.67%) |
| 2023 | $5.59 | $2.25 | (59.75%) | +26.19% | (85.94%) |
| 2022 | $18.00 | $5.59 | (68.94%) | (18.17%) | (50.77%) |
| 2021 | $60.50 | $18.00 | (70.25%) | +28.74% | (98.99%) |
| 2020 | $121.00 | $60.50 | (50.00%) | +18.37% | (68.37%) |
| 2019 | $190.50 | $121.00 | (36.48%) | +31.22% | (67.70%) |
| 2018 | $302.00 | $190.50 | (36.92%) | (4.56%) | (32.36%) |
| 2017 | $288.50 | $302.00 | +4.68% | +21.70% | (17.02%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
